BofA analyst Geoff Meacham downgraded LianBio to Underperform from Buy with a price target of $3, down from $5.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LIAN:
- Nanobiotix says LianBio enters NBTXR3 development pact with Johnson & Johnson
- LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
- LianBio downgraded to Hold from Buy at Jefferies
- LianBio announces departure of CFO Larson, Gu appointed interim CFO
- LianBio Announces Departure of Chief Financial Officer